JPMorgan adds this 'unloved' value stock to its favorite buys list
JPMorgan analyst Jeffery Zekauskas added Celanese to its favorite buys list, keeping an overweight rating and raising its price target to $76 from $68, citing expected 2026 earnings gains from Acetyl Chain price inflation and improving Engineered Materials volumes. Celanese shares are down about 10% in 2026 after a Q2 beat, with leverage concerns. LSEG shows 10 of 18 analysts rated buy/strong buy.
How this was made
The 30-second read
Why it matters
This is a sell-side catalyst: a maintained overweight rating plus a higher price target, supported by specific segment and end-market growth assumptions, while acknowledging leverage as a key overhang.
Market read
Traders may use the PT raise and segment thesis to gauge near-term sentiment, but leverage concerns and the fact it is an analyst action limit fundamental re-rating immediacy.
What to watch
Engineered Materials improvement is described as partly driven by “easy comparisons” and demand trends; if those normalize or leverage worsens, the PT upside may compress despite the overweight call.
Background
JPMorgan analyst Jeffery Zekauskas added Celanese to the bank’s focus list, citing 2026 Acetyl Chain earnings lift and improving Engineered Materials volumes.
Ticker impact
JPMorgan added Celanese to its focus list, keeping an overweight rating and raising its price target to $76 from $68.
Near-term bias to support CE on upgrade/target-follow-through, but magnitude likely limited since it is an analyst action, not a new company disclosure.
The article provides a specific JPMorgan rating and price-target change plus a detailed 2026 thesis (acetic acid derivative pricing, volume improvement, and end-market demand). However, it does not introduce new primary company guidance beyond noting already-reported Q2 results.
Market effects
Could modestly improve sentiment toward specialty chemicals and engineered materials names if investors treat the thesis as read-across for acetic acid derivative pricing and end-market demand.
No clear regional catalyst beyond US-listed analyst coverage.
Limited; the thesis is company-specific (Acetyl Chain, VAM/VAE) with only broad chemical-cycle implications.
Counterpoint
The bullish thesis leans on price inflation and volume recovery, but the article flags investor concern about financial leverage and high net debt-to-EBITDA, which can cap multiple expansion.
Key entities
- companyCelanese
Chemicals and specialty materials maker added to JPMorgan’s focus list with an increased price target.
- financial_institutionJPMorgan
Brokerage firm issuing the focus-list update and price-target increase.
- analystJeffery Zekauskas
JPMorgan analyst who maintained overweight and raised the price target to $76 from $68.
